ALKS

34.08

2.18% -0.76

Handel nachbörslich: 34.26 0.18 +0.53%

Alkermes Plc (ALKS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ALKS? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$34.84

Offen:

$34.57

24-Stunden-Volumen:

2.01M

Relative Volume:

0.87

Marktkapitalisierung:

$5.68B

Einnahmen:

$1.48B

Nettoeinkommen (Verlust:

$241.66M

KGV:

23.79

EPS:

1.4325

Netto-Cashflow:

$480.33M

1W Leistung:

+13.03%

1M Leistung:

+19.04%

6M Leistung:

+9.97%

1J Leistung:

+13.37%

1-Tages-Spanne:

$33.93

$34.99

1-Wochen-Bereich:

$32.54

$36.48

52-Wochen-Spanne:

$25.16

$36.48

Alkermes Plc Stock (ALKS) Company Profile

Firmenname

Alkermes Plc

Sektor

Healthcare (1116)

Branche

Drug Manufacturers - Specialty & Generic (84)

Telefon

00-353-1-772-8000

Adresse

CONNAUGHT HOUSE, DUBLIN 4

Mitarbeiter

2,050

Twitter

@alkermes

Nächster Verdiensttermin

2024-10-24

Neueste SEC-Einreichungen

ALKS's Discussions on Twitter

Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALKS Alkermes Plc	34.08	5.81B	1.48B	241.66M	480.33M	1.4325
TAK Takeda Pharmaceutical Co Adr	18.22	59.20B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	118.26	49.79B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.92	44.27B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	29.82	35.03B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	559.65	24.75B	3.18B	1.33B	1.04B	27.90

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-24	Eingeleitet	Wolfe Research	Outperform
2025-11-11	Eingeleitet	Truist	Buy
2025-09-26	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2025-09-03	Eingeleitet	Wells Fargo	Overweight
2025-07-15	Eingeleitet	Goldman	Buy
2025-06-17	Hochstufung	UBS	Neutral → Buy
2025-05-28	Eingeleitet	Needham	Buy
2025-03-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2025-03-04	Hochstufung	UBS	Sell → Neutral
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-11-05	Hochstufung	Stifel	Hold → Buy
2024-06-17	Eingeleitet	TD Cowen	Buy
2024-03-19	Eingeleitet	Robert W. Baird	Outperform
2024-02-20	Herabstufung	UBS	Neutral → Sell
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-10-24	Hochstufung	Evercore ISI	In-line → Outperform
2023-10-17	Eingeleitet	UBS	Neutral
2022-11-03	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-14	Hochstufung	BofA Securities	Underperform → Neutral
2022-08-16	Eingeleitet	Piper Sandler	Neutral
2022-04-22	Fortgesetzt	Goldman	Buy
2022-04-20	Eingeleitet	Goldman	Buy
2022-01-27	Hochstufung	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Eingeleitet	Citigroup	Neutral
2021-10-07	Hochstufung	Jefferies	Hold → Buy
2021-09-02	Herabstufung	BofA Securities	Neutral → Underperform
2020-10-15	Hochstufung	Mizuho	Neutral → Buy
2020-07-30	Herabstufung	Goldman	Neutral → Sell
2020-02-14	Herabstufung	BofA/Merrill	Buy → Neutral
2020-02-14	Bestätigt	H.C. Wainwright	Neutral
2020-02-14	Herabstufung	JP Morgan	Overweight → Neutral
2020-02-06	Eingeleitet	Mizuho	Neutral
2020-01-31	Hochstufung	Wolfe Research	Underperform → Peer Perform
2019-09-05	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Hochstufung	Goldman	Sell → Neutral
2019-05-31	Eingeleitet	H.C. Wainwright	Neutral
2019-05-01	Herabstufung	Citigroup	Buy → Neutral
2018-12-19	Herabstufung	Goldman	Neutral → Sell
2018-12-14	Eingeleitet	Wolfe Research	Underperform
2018-12-13	Herabstufung	Credit Suisse	Outperform → Underperform
2018-11-05	Eingeleitet	Piper Jaffray	Neutral
2018-08-07	Eingeleitet	Stifel	Hold
2018-06-21	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Eingeleitet	B. Riley FBR, Inc.	Buy
2018-05-16	Hochstufung	Citigroup	Neutral → Buy
2018-05-11	Eingeleitet	BofA/Merrill	Buy

Alle ansehen

Alkermes Plc Aktie (ALKS) Neueste Nachrichten

05:04 AM

Alkermes (NASDAQ: ALKS) 2026 proxy outlines CEO change, $1.48B 2025 revenue and Avadel acquisition - stocktitan.net

05:04 AM

04:16 AM

Alkermes plc (NASDAQ: ALKS) Form 144 lists affiliate sale amounts - stocktitan.net

04:16 AM

05:23 AM

Is Alkermes (ALKS) Building a Durable Sleep-Disorder Franchise With Its Brilliance Phase 3 Bet? - simplywall.st

05:23 AM

05:03 AM

Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program - CSRwire

05:03 AM

Apr 03, 2026

Alkermes Starts Phase 3 Program for Narcolepsy Drug Candidate Alixorexton - Sleep Review

Apr 03, 2026

Apr 02, 2026

Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - marketbeat.com

Apr 02, 2026

ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill

Apr 02, 2026

Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN

Apr 02, 2026

Top 2 Health Care Stocks That May Implode In April - Sahm

Apr 02, 2026

Apr 01, 2026

Alkermes launches phase 3 trials for narcolepsy drug alixorexton By Investing.com - Investing.com Australia

Apr 01, 2026

Alkermes stock hits 52-week high at $36.46 By Investing.com - Investing.com Canada

Apr 01, 2026

Alkermes launches phase 3 trials for narcolepsy drug alixorexton - Investing.com

Apr 01, 2026

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 - Yahoo Finance

Apr 01, 2026

Alkermes (ALKS) Nears 52-Week High on Increasing Orexin Receptor Market Interest - Insider Monkey

Apr 01, 2026

Mar 31, 2026

10 Stocks Dominating Today’s Market Surge: ImmunityBio, Alkermes, and More - Insider Monkey

Mar 31, 2026

Highs Report: What is the target price for Alkermes plc stockEntry Point & Technical Pattern Based Signals - baoquankhu1.vn

Mar 31, 2026

Lilly shifts from obesity to narcolepsy with $7.8B Centessa buy - BioWorld MedTech

Mar 31, 2026

Alkermes Shares Surge 15% Following Lilly-Centessa Deal - Intellectia AI

Mar 31, 2026

Alkermes’ Future: Critical Developments and Financial Outlook - timothysykes.com

Mar 31, 2026

Alkermes (ALKS) Shares Surge by Nearly 18% in Market Rally - GuruFocus

Mar 31, 2026